Cancer is not one disease—and “the tumour got smaller” is not the whole outcome.
Cancer can begin in many tissues, arise through different molecular changes, behave differently even within the same organ and require very different combinations of surgery, radiotherapy, medicines, monitoring, rehabilitation and supportive care. Some cancers can be prevented. Some are found by screening. Some present through symptoms. Some are highly curable; others become long-term conditions or serious illnesses requiring palliative support.
This Learning Map treats oncology as a movement system across the wider Medicine Web. It does not reproduce private disease machinery or provide individual cancer advice. Its purpose is to show how a cancer question moves from risk to evidence, diagnosis, treatment, human outcome and return.
Wait, What? “Cancer” Is a Family Name
The World Health Organization describes cancer as a large group of diseases characterised by abnormal cells that grow beyond usual boundaries and may invade nearby tissue or spread to other organs. WHO’s 2026 global cancer report emphasises the full continuum: prevention, early detection, diagnosis, treatment, palliative care and survivorship.
For eduKateAI, that means the first routing question is not merely “Does this person have cancer?” but what cancer object are we dealing with—risk, screening finding, suspicious lesion, pathology diagnosis, stage, biomarker, treatment, response, recurrence or survivorship state?
The Oncology Tube
Risk and prevention → screening where evidence supports it → symptom or abnormal finding → imaging/laboratory evaluation → tissue or cellular diagnosis → pathology classification → stage and extent → molecular/biomarker characterisation where relevant → multidisciplinary treatment planning → surgery/radiotherapy/systemic treatment → toxicity and supportive care → response assessment → surveillance → survivorship or recurrence → palliative care where needed → population learning and prevention.
1. Prevention and Screening Are Different Objects
Prevention aims to reduce the chance that cancer develops. Screening aims to detect selected cancers or precancerous states in people without symptoms when evidence shows that the programme can improve outcomes.
Not every cancer has a useful population screening test. Singapore MOH’s 2026 Screening Test Review Committee update explicitly distinguishes recommended screening for common cancers from targeted screening for selected high-risk groups. eduKateAI should therefore never infer “earlier is always better” without checking evidence, population and follow-up pathway.
Current Singapore screening questions should route to MOH and Healthier SG rather than to copied age tables that may become stale.
2. A Screening Result Is Not a Cancer Diagnosis
Screening can identify abnormal mammograms, positive stool tests, cervical abnormalities or other signals. These results create a diagnostic pathway; they do not automatically establish cancer.
For eduKateAI, the chain must preserve: screening test → result → confirmatory investigation → pathology or other diagnostic evidence → final diagnosis.
3. Symptoms and Signs Begin With Uncertainty
Weight loss, bleeding, a lump, persistent pain, altered bowel habits, cough, neurological symptoms and many other concerns can have cancerous and non-cancerous explanations. Primary Care owns the first-contact differential for many presentations.
The Primary Care Web therefore sits upstream of many oncology routes.
4. Imaging Finds Structure; Pathology Establishes Many Diagnoses
Imaging can reveal a mass, define anatomy, identify spread, guide biopsy and monitor response. But an image is not identical to tissue diagnosis. Histopathology, cytology and molecular testing can determine tumour type, grade and other characteristics.
The Imaging Web owns image acquisition and interpretation architecture. The Laboratory & Diagnostics Web owns specimen identity, measurement and result lineage.
5. The Specimen Is a Critical Lineage Object
A biopsy may pass from procedure room to pathology laboratory, through fixation, sectioning, staining and sometimes molecular analysis before returning as a diagnosis. Patient identity, anatomical site and specimen orientation must remain intact throughout.
For eduKateAI, a pathology result should never be detached from which tissue, which site, which date and which method.
6. Stage Asks How Far the Disease Extends
Staging systems vary by cancer type, but the purpose is broadly similar: describe local tumour extent, regional involvement and spread to distant sites where relevant. Stage can affect prognosis and treatment choices.
Stage is therefore not the same as tumour type, grade or biomarker status. eduKateAI should keep these representations separate.
7. Biomarkers Can Change Treatment Ownership
Some cancers are further characterised by receptors, mutations, proteins or other biomarkers that may inform prognosis, treatment selection or clinical-trial eligibility. The relevance of a biomarker depends on tumour type, assay quality, evidence and current therapeutic context.
A molecular finding is not automatically an instruction to use a medicine. Evidence and regulatory status still matter.
8. Multidisciplinary Care Exists Because No One Modality Owns Cancer
Cancer care may involve surgeons, medical oncologists, radiation oncologists, pathologists, radiologists, nurses, pharmacists, rehabilitation professionals, dietitians, palliative-care teams and others. The correct combination depends on the disease and the patient.
The architecture should therefore preserve the treatment plan as a shared object while professional authority remains distributed.
9. Treatment Intent Must Be Explicit
A treatment can be curative, adjuvant, neoadjuvant, disease-controlling, symptom-relieving or otherwise supportive. The same intervention can have different intent in different contexts.
For eduKateAI, treatment names without intent are under-specified.
10. Surgery Is One Route, Not the Whole Route
Surgery may remove a primary tumour, obtain diagnostic tissue, reduce tumour burden, manage complications or relieve symptoms. The operative episode must preserve indication, pathology handoff, postoperative state and functional recovery.
The Surgery & Perioperative Medicine Web owns that movement.
11. Radiotherapy Is Physics Becoming Medicine
Radiotherapy uses ionising radiation to damage cancer cells while attempting to limit harm to normal tissue. Planning depends on anatomy, imaging, dose distribution, tumour biology and treatment intent.
This is a strong Science-to-Medicine bridge: radiation physics belongs to Physical World Science; patient-specific planning and delivery belong to authorised oncology and radiation-therapy teams.
12. Systemic Therapy Is a Pharmacy and Evidence Tube
Cytotoxic chemotherapy, endocrine treatment, targeted therapies, immunotherapies and other systemic treatments have different mechanisms, indications, toxicities and monitoring needs.
The Pharmacy Web owns medicine identity, regulation, prescribing, verification, administration and monitoring. The Evidence Web owns claims of benefit and harm.
13. Treatment Toxicity Is Part of the Disease Journey
Myelosuppression, infection risk, nausea, fatigue, neuropathy, organ toxicity, skin effects, endocrine effects and many other adverse outcomes can arise depending on treatment. Monitoring is therefore not administrative; it is part of cancer care.
Acute severe toxicity can cross into the Emergency & Critical Care Web.
14. Response Assessment Needs the Same Object Over Time
Tumour size, metabolic activity, tumour markers, symptoms, function and pathology can all contribute to response assessment depending on disease and therapy. Measurements must remain comparable across time.
A single scan or marker should not be treated as the whole patient outcome.
15. Survivorship Is a Distinct Medicine State
After treatment, people may need surveillance, rehabilitation, management of late effects, cardiovascular or endocrine monitoring, fertility support, mental-health care, return-to-work or school support and preventive health.
The return tube therefore reconnects Oncology to Primary Care and Rehabilitation.
16. Recurrence Is a New State, Not a Reset
If cancer returns, prior treatments, response, toxicities, molecular findings, time since treatment and current function all matter. The patient does not return to the beginning of the original tube.
17. Palliative Care Can Begin Before the Last Treatment
Palliative and supportive care can address pain, breathlessness, nausea, fatigue, anxiety, practical burden and difficult decisions alongside active cancer treatment.
The Palliative & Supportive Care Web owns that serious-illness and goals axis.
18. Cancer Returns to Public Health
Tobacco, alcohol, obesity, physical inactivity, infections such as HPV and hepatitis, occupational and environmental exposures and access to prevention, diagnosis and treatment shape cancer burden across populations. WHO’s 2026 global cancer report explicitly connects clinical outcomes to health-system capacity and inequity.
eduKateAI Oncology Tube Card
- OBJECT: risk, screening result, lesion, pathology diagnosis, stage, biomarker, treatment, response, recurrence or survivorship?
- ANATOMICAL SITE: where did the cancer arise?
- PATHOLOGY: what tissue/cell type and grade?
- EXTENT: what stage or distribution?
- MOLECULAR STATE: which biomarkers matter, by what validated method?
- INTENT: prevention, diagnosis, cure, control, symptom relief or surveillance?
- TREATMENT OWNERS: surgery, radiotherapy, systemic therapy, supportive care or combination?
- TOXICITY: what harm must be monitored?
- RESPONSE: what comparable evidence shows benefit or progression?
- FUNCTION: what happened to daily life, cognition, mobility, nutrition, fertility or work?
- RETURN: survivorship, recurrence, palliative care and primary-care handoff.
- SAFETY: public education must not diagnose cancer or select individual treatment.
Canonical External Sources
- Global cancer burden and continuum: World Health Organization Cancer and the Global Status Report on Cancer 2026.
- Cancer epidemiology and classification research: WHO/IARC.
- Singapore screening policy: Ministry of Health and STRC 2026.
- Evidence: PubMed, clinical trials, systematic reviews and current oncology guidelines.
- Singapore medicines and regulation: HSA and authorised oncology services.
Educational boundary: This page explains oncology information architecture. It does not interpret a personal screening result, diagnose cancer, stage an individual tumour or recommend surgery, radiotherapy or cancer medicines. Those decisions require current pathology, imaging, evidence and qualified oncology teams.